AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 MAR 4 - (NewsRx.com & NewsRx.net) -- In a study conducted over a 5-year period with more than 1,200 women with early-stage endometrial cancer, a team of physicians found that estrogen replacement therapy was associated with a low incidence of endometrial cancer recurrence.
In the largest prospective, randomized, controlled trial to date, 618 women were selected to receive estrogen replacement therapy (ERT) following surgery for stage I or II endometrial cancer and 618 women were selected randomly to receive a placebo. Both groups were treated for 3 years, with an additional 2 years of follow-up. Due to an enrollment drop in the study following the June 2002 publication of the Women's Health Initiative results regarding the risks and benefits of estrogen plus progestin in healthy menopausal women, data were accrued for 1,236 evaluable patients rather than the 2,108 patients originally sought.
Overall, researchers reported at the Society of Gynecologic Oncologist's Annual Meeting on Women's Cancer on February 9, 2004, the study found a low ...
Source: HighBeam Research, ERT poses little recurrence risk for women treated for early-stage...